(1888PressRelease)
November 06, 2008 - Michael Shih, Director of Business Development at Eisai Inc. and Deepa Talpade, Director of Global Licensing & Strategic Alliances at Schering Plough will give the joint featured address entitled “CNS Deal Outlook: What We Can Learn From Recent Trends” at this year’s CNS Diseases Partnering forum.
The presentation will take place in the Recent Deals in CNS session of the conference and will focus on the recent string of deals for novel approaches to treat unmet medical needs in the CNS category. Deals such as the GSK/Actelion (almorexant for insomnia), Astellas/CoMentis (CTS-21166, an oral beta-secretase inhibitor for Alzheimer's Disease), Pfizer/Medivation (dimebon for Alzheimer's Disease and Huntington's Disease), and Eli Lilly/BioMS (MBP8298 for Multiple Sclerosis) will be discussed along with what the immediate future of CNS partnering could look like.
The CNS Diseases Partnering & Deal-Making Summit takes a microscopic look at trends and developments in CNS diseases, from cutting-edge CNS disease research to early and late stage partnerships. Whether you are a business development professional or a CNS disease specialist, this conference will help you grasp a full scope of the market for new treatments and therapies for all types of CNS diseases. For more information visit http://gtcbio.com/conferenceDetails.aspx?id=140.
###
